- Home
- AEON vs DRCT Comparison
AEON vs DRCT Comparison
Compare AEON & DRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEON
- DRCT
- Stock Information
- Founded
- AEON N/A
- DRCT 2018
- Country
- AEON United States
- DRCT United States
- Employees
- AEON N/A
- DRCT N/A
- Industry
- AEON Biotechnology: Pharmaceutical Preparations
- DRCT Computer Software: Programming Data Processing
- Sector
- AEON Health Care
- DRCT Technology
- Exchange
- AEON Nasdaq
- DRCT Nasdaq
- Market Cap
- AEON 8.0M
- DRCT 9.2M
- IPO Year
- AEON N/A
- DRCT 2022
- Fundamental
- Price
- AEON $0.73
- DRCT $0.46
- Analyst Decision
- AEON Strong Buy
- DRCT Strong Buy
- Analyst Count
- AEON 1
- DRCT 1
- Target Price
- AEON $360.00
- DRCT $6.00
- AVG Volume (30 Days)
- AEON 85.9K
- DRCT 791.3K
- Earning Date
- AEON 08-12-2025
- DRCT 08-05-2025
- Dividend Yield
- AEON N/A
- DRCT N/A
- EPS Growth
- AEON N/A
- DRCT N/A
- EPS
- AEON N/A
- DRCT N/A
- Revenue
- AEON N/A
- DRCT $36,459,000.00
- Revenue This Year
- AEON N/A
- DRCT $16.81
- Revenue Next Year
- AEON N/A
- DRCT $62.96
- P/E Ratio
- AEON N/A
- DRCT N/A
- Revenue Growth
- AEON N/A
- DRCT N/A
- 52 Week Low
- AEON $0.38
- DRCT $0.38
- 52 Week High
- AEON $115.57
- DRCT $6.59
- Technical
- Relative Strength Index (RSI)
- AEON 48.08
- DRCT 48.77
- Support Level
- AEON $0.72
- DRCT $0.44
- Resistance Level
- AEON $0.80
- DRCT $0.48
- Average True Range (ATR)
- AEON 0.06
- DRCT 0.04
- MACD
- AEON 0.00
- DRCT 0.01
- Stochastic Oscillator
- AEON 59.94
- DRCT 75.24
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.
About DRCT Direct Digital Holdings Inc.
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.